Pharma & Biotech

Bayer’s stock is caught in a familiar squeeze: strong operational performance and promising drug data are consistently overshadowed by the...

The sell-off in Newron Pharmaceuticals has shown no signs of letting up. Shares closed last Friday at €13.15, marking a...

Bayer delivered a first-quarter earnings report that should have been a catalyst for its stock. Adjusted earnings per share jumped...

The next few months will decide whether BioNTech can turn its sprawling oncology pipeline into a revenue-generating reality. With a...

Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company...

Eli Lilly closed last week with a flurry of news that turned the stock into a tale of two catalysts....

Assembly Biosciences has emerged from the EASL Congress in Barcelona with more than just data. The biotech firm capped a...

Eli Lilly has barrelled past a historic threshold, becoming the first pharmaceutical company to reach a market capitalisation of $1...

Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races...

Ocugen is making quiet but meaningful progress across its pipeline of gene therapy programmes, yet the stock tells a more...